AFL Aflac Incorporated
Aflac Incorporated, through its subsidiaries, provides supplemental health and life insurance products. It operates in two segments, Aflac Japan and Aflac U.S. The Aflac Japan segment offers cancer, medical, nursing care, whole life, and GIFT insurance products, as well as WAYS and child endowment, and Tsumitasu insurance products in Japan. Its Aflac U.S. segment provides accident, disability, cancer, critical illness, hospital indemnity, dental, vision, and life insurance products in the United States. The company also provides hearing, final expense, pet, Medicare supplement, supplemental dental and vision, short-term disability, and absence management insurance products, as well as cafeteria plans. It sells its products to individuals, families, and business owners through individual, independent corporate, and affiliated corporate agencies; banks; independent associates/career agents; and brokers. Aflac Incorporated was founded in 1955 and is headquartered in Columbus, Georgia.…
Industry Peers
Insurance - LifeKey Statistics
About Aflac (NYSE: AFL)
›
Aflac (NYSE: AFL) is listed on the New York Stock Exchange, where its shares trade in USD. It belongs to the Insurance - Life industry, part of the Financial Services sector, and reports about 12,716 employees.
The shares were at 124.76 USD on 19 November 2026, up 13.9% over 52 weeks. Its 52-week range is 105.76 USD to 131.18 USD: the price is 4.9% below the high and 18.0% above the low.
At a market capitalisation of 61.71B USD, it trades at 18.2 times trailing earnings and 16.1 times forward earnings. The median trailing P/E of its 19 largest Insurance - Life peers is 11.4, a premium of 60% for AFL. It pays a dividend yielding 2.04% (it pays out 35% of its earnings), against a median of 2.70% among the dividend payers in that peer group.
Aflac reports return on equity of 12.4%, an operating margin of 27.4% and revenue down 31.0% year over year.
Its debt exceeds its cash by 7.68B USD, a debt-to-equity ratio of 0.29. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health. 15 analysts cover the stock, with an average rating of Hold; their mean price target of 119.87 USD is 3.9% below the current price. The next earnings report is expected on 3 February 2027.